Immunization Efficacy of a Commercialized Inactivated Mycoplasma bovis (Strain HM) Vaccine in Calves at a Large-Scale Dairy Farm in Yancheng, Jiangsu Province
Abstract
Simple Summary Bovine Respiratory Disease (BRD) caused by Mycoplasma bovis (M. bovis) infection results in substantial economic losses to the livestock industry. Therefore, it is urgent to develop effective vaccines to prevent and control M. bovis-positive clinical BRD. To systematically evaluate the efficacy of a commercially available inactivated M. bovis vaccine (strain HM) in the field, a randomized, double-blind, controlled field trial at a large-scale dairy farm in Jiangsu Province was conducted in this study. The results indicated that the vaccine was well-tolerated. Moreover, a booster immunization was effective in inducing specific immune responses, reaching high protective efficacy (61%) against M. bovis-positive clinical BRD. Furthermore, the vaccine significantly reduced the incidence of bovine respiratory disease (BRD) and the infection risks of certain pathogens. These findings demonstrated that the vaccine afforded excellent protection against M. bovis-positive clinical BRD in calves. This study offers important technical support for controlling M. bovis-positive clinical BRD in farms.